#Paris #France #Drug Development #Clarenta Group #Leads To Development

Clarenta Group Strengthens Drug Development Skills with L2D

On October 1, 2026, Clarenta Group announced a major milestone in its journey to enhance its drug development expertise. The group welcomed Leads To Development (L2D) following a significant investment. This strategic move consolidates Clarenta's commitment to supporting biotech and pharmaceutical companies throughout the early phases of drug development, from preclinical strategy to initial human trials and beyond.

The integration of L2D brings specialized knowledge in non-clinical development, manufacturing, and regulatory strategy, particularly during the crucial early stages of drug development. L2D, headquartered in France, provides essential support to innovative companies in the biotechnology and pharmaceutical sectors. Their services include defining development pathways, collecting and evaluating preclinical data, establishing manufacturing processes, and ensuring effective implementation, along with crafting regulatory strategies to advance new therapies towards clinical phases efficiently.

With L2D's expertise, Clarenta reinforces its existing capabilities in early drug development consulting and its specialized unit for early-phase operations, effectively bridging the gap between initial scientific strategies and the execution of early clinical research.

This partnership marks a significant step in the strategic vision of Clarenta, which recently rebranded itself to reflect its evolution into a comprehensive partner for biotech and pharmaceutical sponsors focused on early-stage development. Despite the merger, L2D will continue to operate from its Paris headquarters, providing its clients with dedicated support while leveraging the broader resources available within Clarenta's extensive network.

Insights from Leadership

Chris Smyth, CEO of Clarenta, commented on the acquisition: "The integration of L2D represents a pivotal advancement in shaping the future of Clarenta. Our aim is to assist clients in navigating complexities from the very onset of development. L2D brings profound expertise in non-clinical areas, manufacturing, and regulatory frameworks, complementing our existing strengths and helping sponsors connect preclinical decisions with the realities of early clinical development."

Jonathan Kearsey, the co-founder and CEO of L2D, shared his excitement about the partnership: "This thrilling collaboration allows L2D to maintain its focus on mastering non-clinical development—our specialty—while benefiting from Clarenta's vast clinical experience. Our clients rely on us to solve intricate scientific and regulatory questions in the early phases of development. By joining forces with Clarenta, we can connect these preclinical decisions to clinical strategies that will ensure optimal, risk-managed, and successful programs."

Christopher Backes, co-founder of EdgeCap Partners, the majority investor in Clarenta, emphasized, "L2D fits perfectly within Clarenta’s strategy. This partnership grants us specialized skills right from the initial steps of the development process, at a time when the relevance of decisions can create significant value for clients, while preserving the focused expertise that has made L2D successful."

About Clarenta

Clarenta, formerly known as Comac Medical Group, is a European partner specializing in clinical development, aiding biotech and pharmaceutical firms in navigating the complexities of clinical development with clarity and confidence. Clarenta combines early development strategies, regulatory knowledge, and clinical execution from phase I studies to clinical implementation throughout Europe. For more information, visit www.clarenta.com.

About Leads To Development

Based in Paris, France, Leads To Development (L2D) provides specialized consulting services in non-clinical development and regulation, with tangible operational assistance. For over 15 years, L2D has empowered biotech and pharmaceutical companies to excel in the early phase of their drug development processes. More details can be found at www.leadstodevelopment.com.